Search results
-
Nuvation gets in before Nuvalent
… has 11 to 20-fold selectivity for ROS1 over TRK. In an ESMO 2024 poster Nuvalent put this at a more conservative …
- 06/12/2025 - 15:10 -
ASCO 2025 – BioNTech’s latest Claudin6 effort falls short
… *another 4 responses were unconfirmed. Source: ASCO 2025 & ESMO 2024. Complicating the cross-trial comparison …
- 06/01/2025 - 21:08 -
Another TIGIT bites the dust
… + Jemperli, vs Jemperli ORR ORR improvement at ESMO 2024; no meaningful improvement in PFS, as per May 2025 …
- 05/14/2025 - 15:34 -
Qilu nabs a new B7-H3 contender
… China ph3s in SCLC & head & neck Looked competitive at ESMO 2024 in SCLC MHB088C Minghui/ Qilu Topo1 …
- 05/13/2025 - 16:22 -
AACR 2025 preview – distressed biotechs seek redemption
… Ph1 in KRAS G12D-resistant NSCLC Had data at ESMO 2024 IK-595 MEK-RAF molecular glue Ikena …
- 03/28/2025 - 08:55 -
Acrivon CHKs itself
… 2 trial of ACR-368 Mar 2025 update ESMO 2024 Patient subgroup BM+ BM- …
- 03/27/2025 - 13:27 -
SGO 2025 – Genmab’s advantage looks Profound
… cohort B1 results SGO 2025 ESMO 2024 Cutoff date 15 Jan 2025 28 Jul …
- 03/20/2025 - 16:08 -
Merck and Sanofi sound the alarm for ILT inhibition
… of BND-22 had posted “encouraging results”. However, an ESMO 2024 presentation suggests otherwise and there must now …
- 03/07/2025 - 18:26 -
GSK and Hansoh press on despite Pfizer’s exit
… AstraZeneca ADC Ph1/2 underwhelmed at ESMO 2024, with ORR 25% in ≥25% expressers …
- 03/06/2025 - 13:28 -
Bristol exits KRAS G12D
… Astellas Degrader Lacklustre ph1 data at ESMO 2024; proof-of-concept judgement due in H1 2025 …
- 03/06/2025 - 13:30
